Galectin Therapeutics Announces Research Collaboration with Dr. Jose Jalife of the University of Michigan Medical School to Explore Role of Galectins in Cardiovascular Disease
Published: Jul 21, 2011
NEWTON, Mass.--(BUSINESS WIRE)--Galectin Therapeutics Inc. (OTC: GALT) today announced that it has entered into a research collaboration with Dr. Jose Jalife of the University of Michigan Medical School to better understand the relationship of Galectin-3 to cardiac fibrosis in chronic cardiac arrhythmias. Galectin-3 is known to be increased in patients with heart failure and is believed to be a critical mediator in the development of cardiac fibrosis. Understanding of these mechanisms could ultimately lead to new therapeutic approaches, including galectin inhibition, to cardiac fibrosis and chronic arrhythmias.